dichlororibofuranosylbenzimidazole has been researched along with Benign Neoplasms, Brain in 1 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dixit, D | 1 |
| Sharma, V | 1 |
| Ghosh, S | 1 |
| Mehta, VS | 1 |
| Sen, E | 1 |
1 other study available for dichlororibofuranosylbenzimidazole and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition.
Topics: Apigenin; Apoptosis; Brain; Brain Neoplasms; Casein Kinase II; Cell Cycle Checkpoints; Cell Line, Tu | 2012 |